The pioneer of messenger RNA therapeutics, Moderna Inc. (
MRNA) today announced the completion of enrollment for both cohorts (healthy younger adults ages 18-55 (n=300) and the sentinel group of older adults ages 55 years and above (n=50)) of the phase 2 study of its vaccine candidate (mRNA-1273) against *redacted* The cohorts of older adults (ages 56-70, n=30) and elderly adults (ages 71 and above, n=30) in NIH-led Phase 1 study have also completed enrollment.